Skip to main content
TurkeyStemcell
Regenerative medicine / Istanbul, Turkey

Wharton's Jelly Stem Cell Therapy in Turkey

The most potent and ethically sourced mesenchymal stem cells in clinical use today — collected from umbilical cord tissue, GMP-processed, and delivered at our regenerative medicine clinic in Istanbul.

Request Free ConsultationWhatsApp Us
A closer perspective
Illustrative film of how a cell preparation is made, checked and released.
Your goals. An individual medical review.Explore this treatment

What Are Wharton's Jelly Stem Cells?

Wharton's jelly is the gelatinous connective tissue that surrounds the blood vessels of the umbilical cord. It contains a remarkably rich population of mesenchymal stem cells (MSCs) — adult stromal cells capable of differentiating into bone, cartilage, muscle, and fat lineages and, more importantly for clinical use, releasing powerful paracrine signaling molecules that modulate inflammation, support tissue repair, and regulate the immune system.

Because Wharton's jelly MSCs (WJ-MSCs) are neonatal, they retain longer telomeres, stronger proliferative capacity, and more robust paracrine output than mesenchymal stem cells harvested from adult tissues such as bone marrow or adipose. They are also immunologically privileged — meaning they can be used allogeneically (donor-to-recipient) without HLA matching and without immunosuppression.

Conceptual illustration of mesenchymal stromal cell morphology.

Why Wharton's Jelly MSCs Outperform Adult Stem Cells

Neonatal potency

Younger biological age means longer telomeres, higher proliferative capacity, and stronger paracrine signaling output than adult bone-marrow or adipose MSCs.

Superior anti-inflammatory profile

WJ-MSCs secrete higher concentrations of IL-10, TGF-β, IDO, and PGE2 — the molecular drivers of immune modulation and inflammation resolution.

Immunologically privileged

Low HLA-II expression makes WJ-MSCs safe for allogeneic infusion without HLA matching or immunosuppression.

Scalable & standardizable

A single umbilical cord can yield billions of cells through GMP expansion — enabling reproducible dose-standardized clinical batches.

Ethically sourced

Collected after healthy full-term births with informed maternal consent from tissue that would otherwise be discarded.

Excellent safety record

Published clinical safety data across hundreds of trials shows extremely low rates of serious adverse events.

How Wharton's Jelly Stem Cells Are Processed

Cell quality begins with sourcing and ends with characterization. Every batch of WJ-MSCs delivered at TurkeyStemcell follows the same GMP-aligned pipeline:

  1. 1

    Ethical collection

    Umbilical cord collected after healthy full-term delivery with informed maternal consent and full infectious-disease donor screening.

  2. 2

    Cold-chain transport

    Cord transported to a GMP-certified laboratory under validated cold chain within hours of collection.

  3. 3

    Dissection & enzymatic digestion

    Wharton's jelly is dissected from the umbilical cord vessels and processed through a standardized enzymatic protocol to release the MSC population.

  4. 4

    Expansion under GMP

    MSCs are expanded in xeno-free, defined media to clinically relevant cell counts. Passage number is strictly limited to preserve genomic stability.

  5. 5

    Quality control

    Every batch is tested for viability (≥90%), identity (CD73+ / CD90+ / CD105+ and CD34− / CD45−), sterility (USP <71>), endotoxin (USP <85>), mycoplasma, and karyotype.

  6. 6

    Cryopreservation & clinical release

    Released batches are cryopreserved in DMSO-based clinical-grade media. Cells are thawed and prepared for administration on the day of treatment.

Clinical Applications of Wharton's Jelly Stem Cells

WJ-MSCs are explored as part of regenerative protocols across many indications. Each program at TurkeyStemcell is personalized after specialist review:

Multiple SclerosisParkinson's DiseaseALSAutism SupportCerebral PalsyKnee OsteoarthritisRheumatoid ArthritisLupusCrohn's DiseaseType 2 DiabetesCOPDAnti-Aging Wellness

Wharton's Jelly — Frequently Asked Questions

Wharton's jelly is the gelatinous connective tissue that cushions and surrounds the two arteries and one vein inside the human umbilical cord. It is made primarily of mucopolysaccharides — hyaluronic acid and chondroitin sulfate — together with collagen fibers and a uniquely rich population of mesenchymal stem cells. It was first described by the English physician Thomas Wharton in 1656.

Wharton's jelly is composed of a hydrated proteoglycan matrix (mainly hyaluronic acid and chondroitin sulfate), collagen types I, III and VI, fibroblast-like stromal cells, and a high-density population of mesenchymal stem cells (MSCs). This matrix gives the umbilical cord its springy, gel-like texture and protects the cord vessels from compression during pregnancy.

Biologically, Wharton's jelly protects the umbilical cord vessels from kinking and compression, regulates blood flow to the fetus, and serves as a reservoir of stem and progenitor cells. In regenerative medicine, the same tissue is processed to isolate Wharton's jelly mesenchymal stem cells (WJ-MSCs), which are used clinically for their anti-inflammatory and tissue-supportive paracrine signaling.

Wharton's jelly is found exclusively inside the umbilical cord, between the umbilical vessels and the outer amniotic epithelium. It is not present in the placenta or in adult tissues — its availability is limited to the moment of birth, which is why ethically collected umbilical cords are the only source of true WJ-MSCs.

Wharton's jelly stem cells are mesenchymal stem cells (MSCs) sourced from Wharton's jelly — the gelatinous connective tissue surrounding the blood vessels of the umbilical cord. They are ethically collected after healthy, full-term births with informed maternal consent. Wharton's jelly MSCs (WJ-MSCs) are considered among the most potent and proliferative MSC populations available for clinical use.

WJ-MSCs offer several advantages over bone-marrow– or adipose-derived adult MSCs: (1) they are neonatal cells with longer telomeres and stronger proliferative capacity, (2) they have superior anti-inflammatory and immunomodulatory properties, (3) they are immunologically privileged (low HLA-II expression) making them safe for allogeneic use without HLA matching, (4) they are collected non-invasively from material that would otherwise be discarded, and (5) they can be banked, expanded, and dose-standardized in GMP laboratories.

In the United States, Wharton's jelly–derived mesenchymal stem cell injections are not FDA-approved as a drug. The FDA has issued guidance that minimally manipulated, homologous-use cord-tissue products fall under Section 361 of the PHS Act, while expanded MSC products are regulated as biologic drugs requiring an Investigational New Drug (IND) application. Turkey regulates the same cells under Ministry of Health licensing, which is why international patients travel to Istanbul for treatment.

WJ-MSCs have an excellent published safety profile across hundreds of clinical studies. Because they are immunologically privileged, allogeneic use does not require HLA matching or immunosuppression. Common transient effects include mild low-grade fever or fatigue lasting 24–48 hours. Serious adverse events are extremely rare when cells are sourced and processed in GMP-certified facilities such as those used by TurkeyStemcell.

Wharton's jelly content inside the umbilical cord can only be influenced during pregnancy — primarily through maternal nutrition, hydration and avoidance of smoking. Once the cord is delivered, the amount of Wharton's jelly is fixed. For patients, what matters clinically is not 'increasing' Wharton's jelly but receiving a properly dosed, GMP-characterized WJ-MSC product.

Yes. Fresh Wharton's jelly contains a viable, adherent population of mesenchymal stem cells. After GMP processing and controlled cryopreservation, cell viability of ≥90% is routinely maintained at the time of clinical administration.

Yes. Wharton's jelly is part of the umbilical cord, which is routinely discarded after delivery. Collection requires no harm to mother or newborn and is performed only with informed maternal consent at the time of birth. There are no embryonic, fetal, or invasive sourcing concerns — these are post-natal, ethically harvested cells.

Clinical and translational research supports the use of WJ-MSCs across neurological conditions (multiple sclerosis, Parkinson's disease, ALS, stroke recovery, TBI, spinal cord injury, cerebral palsy, autism support), orthopedic conditions (knee osteoarthritis, joint cartilage support), autoimmune conditions (rheumatoid arthritis, lupus, Crohn's disease), pulmonary conditions (COPD), endocrine support (Type 1 and Type 2 diabetes), and anti-aging and wellness protocols.

Routes of administration are selected based on the clinical target: intravenous (IV) infusion for systemic conditions, intrathecal injection (via lumbar puncture) for central nervous system targeting, intra-articular injection for joints, and localized injection for site-specific tissue support. Many advanced protocols combine multiple routes within a single program.

Clinical doses are typically expressed as cells-per-kilogram body weight (cells/kg) or total cell count. Most protocols deliver 1–2 million viable WJ-MSCs per kilogram body weight per session, equivalent to approximately 70–200 million cells per adult patient. Your specialist will recommend the precise dose based on indication, body weight, and route of administration.

After ethical collection, the umbilical cord is transported under cold chain to a GMP-certified laboratory. Wharton's jelly is dissected, enzymatically digested, and MSCs are isolated through a standardized adherence and expansion protocol. Each batch undergoes quality control: viability (≥90%), identity (CD73+/CD90+/CD105+ and CD34−/CD45− surface markers), sterility (USP <71>), endotoxin (USP <85>), mycoplasma testing, and karyotype stability.

Wharton's jelly MSC treatment at TurkeyStemcell is priced by cell dose, from €4,950 (25 million cells) to €19,500 (250 million cells); most complete programs fall between €7,000 and €18,000, and hospital-based neurological programs range up to €25,000. Equivalent Wharton's jelly stem cell injections in the United States typically range from US$15,000 to US$40,000 per session, when available. See our stem cell therapy cost page for a full breakdown.

TurkeyStemcell operates a fully equipped regenerative medicine clinic in Istanbul, Turkey, serving international patients from 40+ countries. Our facility includes GMP-certified cell processing, specialist consultation, multilingual care coordination, and structured remote follow-up. Book a free consultation to receive a personalized protocol recommendation.

Related searches answered on this page

The questions patients most often ask alongside "Wharton's jelly" — answered above, with deeper guides linked where helpful.

What is Wharton's jelly made ofWhat is the function of Wharton's jellyWhere is Wharton's jelly foundWharton's jelly vs bone marrow stem cellsUmbilical cord stem cell therapyMesenchymal stem cell therapyWharton's jelly stem cell therapy cost
Free case reviewIstanbul, TurkeyReply within 24–48 hoursStem cells & exosomes

Explore a Wharton's Jelly Stem Cell Protocol

Free, no-obligation consultation with our regenerative medicine specialists. Personalized protocol recommendation within 24 hours.

Request Free ConsultationWhatsApp Us

Or call directly: +90 534 856 92 92

Animations are optional.

Optional analytics is off until you choose.

May we use Google Analytics cookies to count interactions such as consultation requests and contact-button clicks? Your choice is optional and does not affect access to our services. You can change it here at any time. Read our privacy policy.